MeiraGTx Holdings plc, established on May 1, 2018 under the laws of the Cayman Islands, is a vertically integrated clinical-stage gene therapy company. It boasts six clinical development programs alongside an extensive pipeline of preclinical and research projects. The company has developed core capabilities in viral vector design, optimization, and gene therapy manufacturing, as well as a promising translational gene regulation platform technology that enables precise, dose-responsive control of gene expression through oral small molecules, achieving a dynamic range exceeding 5,000-fold. Initially, MeiraGTx focuses on three therapeutic areas with significant unmet medical needs: ocular diseases—including inherited retinal disorders and major degenerative eye conditions—neurodegenerative diseases, and severe dry mouth syndrome. For more information, visit their website at http://www.meiragtx.com. The company is headquartered at 450 East 29th Street, 14th Floor, New York, NY 10016.

Complete your account application and verification in just 1 minute. The process is fully self-service and available on both RockFlow App and Web.

Once your account has been verified, you can deposit funds into your account using your preferred payment method.

Search for MGTX via RockFlow App or Web, enter the amount you want to invest, and tap Confirm to execute the trade.